Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center.

scientific article published on June 2016

Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/1744-9987.12430
P698PubMed publication ID27312908

P50authorJakob GubenšekQ43289012
P2093author name stringJelka Lindic
Damjan Kovac
Rafael Ponikvar
Aljosa Kandus
Jadranka Buturovic-Ponikvar
Miha Arnol
Karmen Romozi
Andreja Ales Rigler
P2860cites workAdverse events in apheresis: An update of the WAA registry dataQ26771588
Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trialQ33584895
Revisiting traditional risk factors for rejection and graft loss after kidney transplantationQ35250310
Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejectionQ36752176
Banff 2011 Meeting report: new concepts in antibody-mediated rejectionQ37058043
The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review.Q38049098
Antibody-mediated vascular rejection of kidney allografts: a population-based studyQ38062614
Antibody-mediated graft injury: complement-dependent and complement-independent mechanisms.Q38169496
New insights in antibody-mediated rejectionQ38248369
Intravenous immunoglobulin in kidney transplantationQ38625172
Banff 07 classification of renal allograft pathology: updates and future directionsQ40121163
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failureQ43918875
Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experienceQ44103494
A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejectionQ44197767
Impact of rituximab therapy for treatment of acute humoral rejectionQ45361905
Early versus late acute antibody-mediated rejection in renal transplant recipients.Q46415040
Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantationQ46873864
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal TransplantationQ56907959
P433issue3
P304page(s)240-245
P577publication date2016-06-01
P1433published inTherapeutic Apheresis and DialysisQ15759076
P1476titleTreatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center
P478volume20

Reverse relations

cites work (P2860)
Q64114462C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection
Q47286616Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
Q89782890The Preliminary Results of Bortezomib Used as A Primary Treatment for An Early Acute Antibody-Mediated Rejection after Kidney Transplantation-A Single-Center Case Series
Q58754949Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results

Search more.